Young Plasma Transfusion for Health & Longevity
Evidence Review created on 10/09/2026 using AI4L + evidence-mcp / Sonnet 5.5
Also known as: Young Plasma Infusion, Young Blood Transfusion, Young Donor Plasma, Young Fresh Frozen Plasma, Young FFP
Motivation
Young plasma transfusion is the intravenous infusion of plasma, the liquid part of blood, collected from donors typically in their late teens to twenties and given to older recipients. It draws interest because signals carried in the blood are thought to change with age and to influence how tissues repair themselves, raising the question of whether youthful plasma could slow aspects of aging.
The idea grew out of experiments that joined the circulations of young and old animals, after which researchers tested plasma alone in aged animals and then in people with Alzheimer’s disease. Commercial clinics began offering the infusions for aging, and small clinical trials followed. A related approach removes a patient’s own plasma and replaces it with a protein solution instead of adding young plasma.
This review examines what animal and human studies report about young plasma transfusion for health and longevity: the benefits and risks studied, the protocols used and the strength of the evidence behind each, framed for health-conscious adults who evaluate interventions carefully.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
Overview commentary, a news analysis, a podcast episode, a magazine article and a clinical study that introduce young plasma transfusion and closely related plasma-based approaches.
-
Modern Vampirism: “Young Blood” Transfusions - Peter Attia
Physician commentary on the animal origins, commercial clinics and small exploratory human studies of young plasma, noting that human efficacy evidence is virtually nonexistent.
-
Young Plasma Decreases Inflammation After Surgery in Trial - Josh Conway
News analysis of a randomized trial of a young-donor plasma protein fraction (a protein preparation from plasma) in joint-replacement patients, with background on parabiosis (surgically joining two animals’ circulations) and the regulator’s warning.
-
Restore Youthfulness & Vitality to the Aging Brain & Body – Dr. Tony Wyss-Coray - Andrew Huberman
Podcast with Stanford neurologist Tony Wyss-Coray on factors in young blood, with show notes citing trials of plasma exchange (replacing a patient’s plasma) and listing Alkahest.
-
The Prospect of Human Age Reversal - William Faloon
Magazine article reviewing recent young plasma studies, including a rat lifespan study the author helped fund; written from a longevity-advocacy publisher’s viewpoint.
-
Interstitial fluid rejuvenation through young-donor plasma exchange in cognitively impaired patients: a pilot safety and feasibility study - Søraas et al., 2026
Pilot replacing 16 to 26 liters of patient plasma (plasma exchange) with plasma from donors aged 18 to 24 in 12 people with mild cognitive impairment (early memory decline); reports feasibility and adverse events.
No qualifying in-depth content was found from Rhonda Patrick (FoundMyFitness lists only two one-minute news stubs, a summary of the Stanford Alzheimer’s plasma trial and a summary of a mouse plasma-dilution study, and no episode treating young plasma in depth) or Chris Kresser (searches of the site returned nothing relevant on young plasma).
Grokipedia
AI-generated encyclopedia entry covering the history of parabiosis, proposed rejuvenating factors, early human trials, commercial clinics and regulatory warnings, with a reference list for follow-up.
Examine
No Examine article exists for young plasma transfusion.
ConsumerLab
No ConsumerLab article exists for young plasma transfusion.
Systematic Reviews
Two systematic reviews (structured searches and appraisals of all available studies) with meta-analysis (a pooled statistical analysis) cover plasma-based treatment in Alzheimer’s disease and transfusion reactions to plasma in general; neither is limited to young-donor plasma.
-
Efficacy and safety of blood derivatives therapy in Alzheimer’s disease: a systematic review and meta-analysis - Fei et al., 2022
Pooled three plasma trials (one young plasma infusion, two plasma exchange) and five antibody-infusion trials in Alzheimer’s; no cognitive benefit beyond chance (not statistically significant).
-
Comparing transfusion reaction rates for various plasma types: a systematic review and meta-analysis/regression - Saadah et al., 2017
Meta-analysis of 48 studies of reactions to plasma in general, not young-donor plasma; pooled allergic reaction rate 92 per 100,000 units transfused.
Mechanism of Action
Young plasma transfusion rests on the premise that blood carries signals that change with age. In heterochronic parabiosis (joining the circulations of a young and an old animal), old mice regained muscle and liver progenitor cell (tissue-replenishing cell) activity (Conboy et al., 2005), while young mice exposed to old plasma formed fewer new nerve cells, linked to CCL11 (a chemokine, a cell-attracting signaling protein) (Villeda et al., 2011). Plasma alone then improved memory in aged mice (Villeda et al., 2014). Candidate young factors include GDF11 (growth differentiation factor 11, a growth-regulating signaling protein), whose effects conflict because earlier detection reagents were not GDF11-specific (Sinha et al., 2014; Egerman et al., 2015), and TIMP2 (tissue inhibitor of metalloproteinases 2, a brain-supporting plasma protein) from umbilical cord plasma (Castellano et al., 2017).
A competing explanation holds that old plasma carries inhibitory factors, so removal matters more than addition: replacing half of old mouse plasma with saline and albumin (the main plasma protein) matched the benefits of heterochronic exchange (Mehdipour et al., 2020), and old blood’s inhibitory effects often exceeded young blood’s benefits (Rebo et al., 2016).
Pharmacologically, plasma is a protein mixture, not a single compound. Its proteins distribute mainly in the bloodstream and interstitial fluid (fluid between cells), are cleared by ordinary protein breakdown rather than liver enzymes such as CYP3A4 (a liver enzyme that breaks down many drugs), and have half-lives (time for the amount to fall by half) from hours (clotting factors) to about three weeks (albumin).
Historical Context & Evolution
Plasma transfusion was developed to replace clotting factors and other plasma proteins; the US Food and Drug Administration (FDA) lists its recognized uses as bleeding with clotting deficits, warfarin reversal, thrombotic thrombocytopenic purpura (a rare clotting disorder) and rare protein deficiencies (FDA update, 2024). Its use for aging grew from parabiosis experiments in animals (surgically joining two animals’ circulations). Mouse work reported restored muscle and liver regeneration (Conboy et al., 2005) and improved memory after plasma injections (Villeda et al., 2014), prompting human testing and, from 2016, a trial using young blood that drew concern (Kaiser, 2016). GDF11 was proposed as a reversing factor for heart enlargement (Loffredo et al., 2013), yet a follow-up study found no such effect, as its old mice had no age-related heart enlargement (Smith et al., 2015). The FDA issued a safety communication in February 2019 (FDA, 2019) and updated it in December 2024, stating it knows of no evidence of clinical benefit (FDA update, 2024). Opinion continues to evolve: the animal data support more than one reading, and human trials have mostly measured safety.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: no human clinical outcome (symptoms, events or function) or lab marker proven to track such outcomes has been shown by trials from more than one independent research group.
Medium 🟩 🟩
No benefit reaches Medium: the human clinical-outcome results come from single small trials (Sha et al., 2019, with Alkahest co-authors; Parker et al., 2020), were exploratory and unadjusted for multiple testing (no correction for the chance of false positives when many outcomes are tested), and the Alzheimer’s disease results were not borne out by a pooled analysis (Fei et al., 2022).
Low 🟩
Everyday function in Alzheimer’s disease ⚠️ Conflicted ⭕️ Not Central to Health & Longevity
Exploratory daily-living scores improved after weekly young plasma infusions in 18 patients with Alzheimer’s disease (Sha et al., 2019; Alkahest co-authors), which bears on dementia care rather than healthy aging. A pooled analysis of blood-derivative trials found no significant cognitive or daily-living benefit (Fei et al., 2022). Net reading: unconfirmed.
Magnitude: Treatment effect from a statistical model that pools within-person and between-group comparisons (half of the patients were open-label, without placebo) and is not adjusted for multiple testing: Functional Activities Questionnaire (caregiver-rated) −4.56 points (95% CI [confidence interval, the range likely to contain the true value] −6.11 to −3.01; lower is better) and Alzheimer’s Disease Cooperative Study Activities of Daily Living scale, mild cognitive impairment version, +3.17 points (95% CI 0.70 to 5.65; higher is better); cognition on the 13-item Alzheimer’s Disease Assessment Scale–Cognitive subscale showed no change (−1.04 points; 95% CI −3.49 to 1.41).
Fluency and quality-of-life scores in Parkinson’s disease ⭕️ Not Central to Health & Longevity
Fifteen people with Parkinson’s disease received young plasma twice weekly for 4 weeks and scored higher on phonemic fluency (letter-based word generation) and better on a stigma quality-of-life subscale (Parker et al., 2020). This bears on Parkinson’s care, not healthy aging; blinded motor scores did not change.
Magnitude: Phonemic fluency rose from 41.1 to 44.7 words right after the infusions and 48.1 four weeks later; the stigma subscale score fell from 7.4 to 6.2 and then 5.5; no control group, and no adjustment for multiple testing.
Speculative 🟨
Immune and inflammatory response to surgery ⭕️ Not Central to Health & Longevity
In 38 older joint-replacement patients, a young plasma protein fraction (indirect: not whole plasma) shifted immune signaling toward less inflammation than placebo (Alkahest co-authors; Gaudilliere et al., 2025). Bears on surgical recovery; unvalidated laboratory outcomes.
Epigenetic age markers
One epigenetic clock (DNA-tag-based age estimate), GrimAge, fell 0.82 years in an 18-person study of umbilical cord plasma concentrate, an indirect product and route (Clement et al., 2022; Betterhumans-affiliated authors). Young-donor plasma data are lacking.
Memory and tissue rejuvenation in animals ⚠️ Conflicted
Young plasma improved memory in aged mice (Villeda et al., 2014); GDF11 restored muscle in one study (Sinha et al., 2014) but inhibited regeneration in another (Egerman et al., 2015). Net reading: inconsistent.
Lifespan extension in rodents ⚠️ Conflicted
Treated rats had no deaths from 26 to 30 months; controls began dying at 26 (Chiavellini et al., 2024). Repeated injections left mouse lifespan unchanged (Shytikov et al., 2014). Net reading: inconsistent; no human data.
Benefit-Modifying Factors
- APOE4 status: APOE4 (lipid-transport gene variant raising Alzheimer’s risk) carriers were 14 of 17 genotyped Stanford trial patients, a prevalence the authors say limits generalizability (Sha et al., 2019); a Mayo Clinic trial paired young APOE3 (common, lower-risk variant) donors with APOE4 recipients (NCT03887741).
- Baseline health: In a randomized plasma-exchange trial (albumin replacement, with or without immunoglobulin, an antibody preparation; not young plasma), baseline biomarkers predicted favorable biological-age change, suggesting larger effects with immunoglobulin when baseline health was poorer (Fuentealba et al., 2025; authors include Circulate Inc. members).
- Sex: No sex-stratified results exist; the Stanford trial used male donors only and enrolled 12 women among 18 patients (Sha et al., 2019).
- Pre-existing conditions: Controlled data come from Alzheimer’s disease (Sha et al., 2019) and joint-replacement surgery (Gaudilliere et al., 2025) cohorts; no published trial has tested efficacy in otherwise healthy older adults.
- Age: The Stanford trial enrolled recipients aged 50 to 90 and donors aged 18 to 30; whether donor age, recipient age or the gap between them changes response is untested in humans (Sha et al., 2019).
Potential Risks & Side Effects
High 🟥 🟥 🟥
Allergic reactions, including urticaria and anaphylaxis
Donor plasma proteins can trigger urticaria (hives, itchy raised skin welts) and, rarely, airway obstruction or anaphylaxis (a severe whole-body allergic reaction) (FDA, 2019). One Stanford trial patient stopped infusions because of urticaria (Sha et al., 2019), and in the Oslo pilot three of 12 patients had generalized urticaria that halted a session (Søraas et al., 2026). Hospital reporting data show allergic reactions as the most frequent type of plasma transfusion reaction (Saadah et al., 2018).
Magnitude: Allergic reactions occurred at 5.6–72.2 per 100,000 plasma units transfused (interquartile range, the span of the middle half of 23 countries’ rates; no control group); apheresis plasma (collected from a donor by machine) carried higher odds than whole-blood-derived plasma (odds ratio, the relative odds compared with a reference group, 1.29; 95% CI 1.19–1.40). In the Stanford trial, urticaria made 1 of 18 plasma recipients (6%) stop infusions versus 0 of 9 placebo recipients.
Medium 🟥 🟥
No risk reaches Medium: the remaining evidence is uncontrolled reporting on plasma in general, or conflicted, very small trials, with no comparison group among young-donor recipients.
Low 🟥
Transfusion-associated circulatory overload (TACO)
TACO (fluid overload causing swelling and breathing difficulty) occurs when the infused volume exceeds what the circulation tolerates, and the FDA singles out people with pre-existing heart disease (FDA, 2019). Evidence is hospital reporting data for plasma in general, not young-donor trials (Saadah et al., 2018).
Magnitude: 0–1.9 per 100,000 plasma units transfused (interquartile range of national rates; no control group).
Transfusion-related acute lung injury (TRALI)
TRALI (sudden lung inflammation within hours of transfusion, often linked to donor antibodies) is uncommon but can be severe; the FDA lists it among plasma risks (FDA, 2019). Rates come from hospital reporting data for plasma in general (Saadah et al., 2018), not young-donor trials.
Magnitude: 0–1.2 per 100,000 plasma units transfused (interquartile range of national rates; no control group).
Febrile and hypotensive reactions
Febrile non-hemolytic reactions (fever and chills without infection) and hypotension (low blood pressure) occur during plasma transfusion, and apheresis-collected plasma was linked to more hypotensive reactions than plasma derived from whole blood (Saadah et al., 2018). The data cover plasma in general, not young-donor trials.
Magnitude: Febrile reactions 0–9.1 and hypotensive reactions 0–0.6 per 100,000 units (interquartile range of national rates; no control group); hypotensive reactions with apheresis versus whole-blood-derived plasma, odds ratio 2.17 (95% CI 1.38–3.41).
Plasma-exchange procedure effects, including low blood calcium
Replacing 16–26 liters of plasma carries known exchange risks. The Oslo pilot (12 patients, no control group) recorded five mild hypocalcemia (low blood calcium) cases, two of them symptomatic, and further events judged consistent with those risks (Søraas et al., 2026; Weinstein, 2001). Calcium supplementation was routine.
Magnitude: Of 59 adverse events across 12 patients (34 grade 1 mild, 17 grade 2, 6 grade 3, 2 grade 4 life-threatening), five were mild hypocalcemia (two of them symptomatic); no control group.
Bleeding or hematoma at the venous access site
Large-volume exchange needs two intravenous lines, and bleeding at the puncture site can follow. The Oslo pilot reported one significant venous-access hematoma (blood collected under the skin) among 12 patients (Søraas et al., 2026), listed among mild grade 1 events. Evidence is one uncontrolled pilot.
Magnitude: 1 of 12 patients had a significant hematoma at the venous access site; no control group.
Mild infusion-related symptoms ⚠️ Conflicted
Headache, dizziness and blood pressure or heart rate changes followed plasma infusions; headache and dizziness occurred only after plasma, without a significant difference (Sha et al., 2019). A placebo-controlled plasma-fraction trial (indirect; Alkahest-affiliated authors) found similar rates (Hannestad et al., 2021). Net reading: no significant excess over placebo.
Magnitude: Any adverse event, plasma (18 patients) versus placebo (9 patients): 94% versus 100%. Treatment-related events, plasma (17 patients) versus placebo (9 patients): hypertension 18% versus 22%, dizziness 12% versus 0%, sinus bradycardia (slow heart rate) 18% versus 11%, headache 18% versus 0%; no statistically significant difference between groups.
Infectious disease transmission
Screened donor plasma carries a small residual risk of infectious-agent transmission, according to the FDA (FDA, 2019). US estimates for general blood donations, not plasma specifically, are about 1 per 1.0–2.0 million donations for HIV (the AIDS-causing virus), hepatitis C and hepatitis B (Steele et al., 2021).
Magnitude: About 1 in 1.6 million (HIV), 1 in 2.0 million (hepatitis C) and 1 in 1.0 million (hepatitis B) per blood donation from general US donors; no control group, and not specific to plasma infusion.
Possible tumor promotion (isolated report)
One of 12 Oslo pilot patients was diagnosed with a rare connective-tissue cancer weeks after treatment; the oncologist judged causation unlikely, though it could not be excluded (Søraas et al., 2026). Basis: uncontrolled single-patient report.
Magnitude: 1 of 12 patients; no control group.
Serious infection after intensive plasma exchange (isolated report)
One of 12 Oslo pilot patients was admitted to hospital with a severe infection and probable liver abscess (a pus-filled pocket in the liver) seven days after nine intensive-phase exchanges; the investigators judged a treatment cause unlikely (Søraas et al., 2026). Basis: uncontrolled single-patient report.
Magnitude: 1 of 12 patients (grade 4, hospital admission); no control group.
Speculative 🟨
Epigenetic age acceleration after plasma removal
Plasmapheresis (machine removal of plasma) without young plasma or albumin replacement raised several epigenetic age readings in a randomized trial of healthy adults (Borsky et al., 2025). Relevance to young-plasma exchange is unknown.
Risk-Modifying Factors
- Genetic variants: No recipient gene variant has been shown to modify risk; IgA deficiency (genetic absence of one antibody class) with anti-IgA antibodies is the recognized exception for severe plasma allergic reactions.
- Baseline biochemistry: The Oslo pilot required normal biochemistry and no infection before each exchange, treating abnormal baseline results as a reason to postpone (Søraas et al., 2026).
- Donor sex: The Oslo pilot screened female donors for antibodies against HLA (human leukocyte antigen, white-cell surface markers) and HNA3 (human neutrophil antigen 3, a white-cell marker) for lung injury risk; recipient sex differences are unreported (Søraas et al., 2026).
- Heart disease: Circulatory overload is more likely in people with pre-existing heart disease (FDA, 2019).
- Older age: Trials enrolled recipients up to 90 years; older adults with reduced heart or kidney reserve may tolerate fluid loads and calcium shifts less well, but no age-stratified safety data exist.
Key Interactions & Contraindications
- Warfarin (vitamin K antagonist, a clot-slowing anticoagulant): Caution. The FDA lists transient warfarin reversal as a plasma indication (FDA update, 2024), so infusion may offset warfarin’s effect (theoretical); INR (international normalized ratio, a clotting-time ratio) checks around infusions are a monitoring option (theoretical).
- Direct oral anticoagulants (oral clot-slowing drugs; apixaban, rivaroxaban) and heparin (injectable clot-slowing drug; enoxaparin): Monitor. Large-volume exchange lowers clotting factors, which may add to bleeding tendency (theoretical).
- Blood-pressure drugs (ACE [angiotensin-converting enzyme] inhibitors such as lisinopril and angiotensin receptor blockers such as losartan, which block a vessel-tightening hormone): Caution (theoretical). Oslo withheld ACE inhibitors pre-session (Søraas et al., 2026); one case report: collapse after exchange on losartan (Ashok Kumar et al., 2020).
- Aspirin and NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen, naproxen): Monitor. Antiplatelet effects (reduced platelet clumping) may add to bleeding at venous access after large exchanges (theoretical).
- Antihistamines (allergy drugs such as cetirizine, diphenhydramine): Monitor (theoretical). They may blunt early allergic signs; the Oslo protocol gave cetirizine after a prior suspected reaction (Søraas et al., 2026).
- Calcium supplements: Beneficial interaction. The Oslo protocol gave 500 mg calcium chewing tablets before each session to offset calcium lowering (Søraas et al., 2026).
- Supplements with antiplatelet effects (fish oil, vitamin E, ginkgo, garlic): Monitor. They may add to bleeding tendency after large exchanges (theoretical).
- Immunoglobulin (IVIG, intravenous immunoglobulin) added to plasma exchange: Caution. Regimens combining exchange with IVIG add a second infusion exposure; one IVIG-related adverse event occurred in the randomized trial (Fuentealba et al., 2025).
Populations who should avoid Young Plasma Transfusion:
- People with a prior severe allergic reaction to plasma, or IgA deficiency with anti-IgA antibodies: avoid (theoretical), risk of severe allergic reaction.
- People with heart disease prone to fluid overload: avoid outside supervised trials, risk of circulatory overload (FDA, 2019); trials excluded heart failure of NYHA (New York Heart Association symptom grade) class II or higher (NCT05068830) or class III–IV (NCT03887741).
- People with active infection: the Oslo protocol required freedom from infection before each exchange (Søraas et al., 2026).
- People with anemia under evaluation: the Oslo protocol postponed treatments until the workup was complete (Søraas et al., 2026).
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Trial or investigational-application setting: The FDA states young-donor plasma outside its listed indications requires an investigator or sponsor with an active Investigational New Drug (IND) application; aimed at unmonitored adverse reactions (inference, not stated by FDA) (FDA update, 2024).
- Donor antibody screening: The Oslo pilot tested male donors for anti-HLA antibodies and female donors for anti-HLA and HNA3, aimed at lung injury (TRALI) (Søraas et al., 2026).
- Prophylactic calcium: 500 mg calcium chewing tablets before each session, with extra calcium for suspected symptoms, aimed at hypocalcemia during exchange; mild cases still occurred (Søraas et al., 2026).
- Antihistamine after prior reactions: 10 mg cetirizine was given to patients with a previous suspected allergic reaction, and the session could be aborted, aimed at recurrent urticaria (effect not reported) (Søraas et al., 2026).
- Withholding ACE inhibitors: Patients on ACE inhibitors did not take them before sessions, a step aimed at hypotension risk during exchange (reason inferred; not stated in the article) (Søraas et al., 2026).
- Observation and emergency readiness: Rooms were equipped for anaphylaxis, the first session was observed 2 hours after the last transfusion began, and staff were phone-reachable for 24 hours, aimed at delayed TRALI and allergic reactions (Søraas et al., 2026).
- Pre-session health checks: Confirming absence of infection and normal recent biochemistry before each exchange, aimed at infection-related and metabolic events (aim inferred, not stated in the article; effect not reported) (Søraas et al., 2026).
- Hepatitis B vaccination offer: Vaccination was offered before treatment, aimed at residual hepatitis B transmission risk (aim inferred, not stated in the article) (Søraas et al., 2026).
- Modest infusion volumes: The Stanford trial infused one 250 mL unit weekly (Sha et al., 2019); limiting volume to reduce circulatory overload, the risk the FDA describes, is an inference, not stated by the authors.
Therapeutic Protocol
No standard protocol exists; the regimens below come from trials and clinics. Parameters without a citation (e.g., timing, cycling, titration steps) reflect common practice.
- Stanford infusion protocol (Wyss-Coray group): 1 unit (about 250 mL) of young fresh frozen plasma (FFP) from male donors aged 18 to 30, once weekly for 4 weeks, then a 6-week washout (treatment-free interval) (Sha et al., 2019).
- Plasma-fraction protocol (Alkahest): 100 mL or 250 mL of the plasma protein fraction GRF6019 daily for 5 consecutive days, repeated after a 3-month interval (Hannestad et al., 2020; Alkahest-affiliated authors).
- Young-donor plasma exchange (Oslo group): 16 to 26 L of patient plasma replaced with plasma from donors aged 18 to 24 across three protocol variants differing in intensity and dose, with calcium before sessions (Søraas et al., 2026).
- Commercial clinic infusions: Ambrosia charged about $8,000 per treatment before closing in 2019 (Attia, 2022); its registered trial (NCT02803554) lists no posted results.
- Plasma exchange with albumin (dilution approach; Kiprov group): Biweekly or monthly therapeutic plasma exchange, with or without intravenous immunoglobulin, in healthy adults over 50 (Fuentealba et al., 2025).
- Time of day: No trial reported an effect of time of day; sessions followed clinic scheduling.
- Half-life: No young-plasma pharmacokinetic study (how the body handles a substance) exists; individual plasma proteins turn over from hours (clotting factors) to about three weeks (albumin), which informs weekly spacing.
- Single versus split dosing: Trials split exposure into weekly 250 mL units (Sha et al., 2019) or daily 5-day courses (Hannestad et al., 2020), and the Oslo pilot used repeated large exchanges (Søraas et al., 2026); no head-to-head comparison exists.
- Genetic variants: APOE4 carriers were most Stanford trial patients, which limits generalizability (Sha et al., 2019), and a Mayo Clinic trial paired young APOE3 donors with APOE4 recipients (NCT03887741).
- Sex: The Stanford trial used male donors only; no analysis of response by recipient sex has been reported (Sha et al., 2019).
- Age: Donors were aged 18 to 30 (Stanford; Sha et al., 2019) or 18 to 24 (Oslo; Søraas et al., 2026), and Stanford recipients 50 to 90; no study compared donor ages.
- Baseline biomarkers: The Oslo pilot required normal recent biochemistry before each exchange, and biochemistry was rechecked about every 3 to 6 procedures (Søraas et al., 2026).
- Pre-existing conditions: Trial recipients had Alzheimer’s disease, mild cognitive impairment or joint-replacement surgery; protocols for otherwise healthy adults are unvalidated.
Discontinuation & Cycling
- Duration: Every human protocol was a fixed-length course (4 weekly infusions, two 5-day courses, or a set exchange series); none was designed as lifelong therapy (Sha et al., 2019; Hannestad et al., 2020).
- Withdrawal effects: None were reported after course completion; the Stanford design included a 6-week washout, and no rebound data exist (Sha et al., 2019).
- Tapering: No tapering protocol exists or is applicable, because courses ended without dose reduction.
- Cycling: The plasma-fraction trial repeated a 5-day course after 3 months (Hannestad et al., 2020); whether repeated cycles maintain any effect is untested.
Sourcing and Quality
- Source and regulation: The FDA has not approved young plasma for aging (FDA update, 2024); trials used plasma from blood-bank donors (Oslo) or investigational plasma fractions (GRF6019), under trial oversight (Søraas et al., 2026; Hannestad et al., 2020).
- Donor selection: Trials specified donor age (18 to 30, or 18 to 24), screening for antibodies in female donors, and collection by plasmapheresis with 4% sodium citrate anticoagulant (Søraas et al., 2026).
- Pathogen safety: Blood products are screened for infectious agents, but the FDA notes a residual risk of infection remains (FDA, 2019).
- Clinics and compounding: No reputable commercial source has been identified; the FDA reports establishments marketing young plasma without evidence of benefit (FDA update, 2024).
- Formulation: Whole fresh frozen plasma, concentrated plasma protein fractions and umbilical cord plasma concentrate are distinct products with different dosing; results do not transfer between them.
Practical Considerations
- Time to effect: Not established; the Stanford trial assessed outcomes after 4 weekly infusions and the plasma-fraction trial at 24 weeks, and no trial has shown when benefit appears in healthy adults (Sha et al., 2019; Hannestad et al., 2020).
- Common pitfalls: Treating plasma exchange with albumin and young-donor plasma infusion as interchangeable, although they test dilution versus addition; reading biomarker shifts as proof of benefit; and sourcing from unregulated clinics.
- Regulatory status: The FDA states plasma from young donors is not approved for aging or memory loss; use outside listed indications requires an investigator or sponsor holding an active IND application (FDA update, 2024).
- Source interests: The FDA-cited Circular of Information (FDA update, 2024) is published by AABB (formerly the American Association of Blood Banks), whose blood-center members handle plasma commercially; Alkahest (plasma developer) co-authored the Stanford (Sha et al., 2019) and surgery (Gaudilliere et al., 2025) trials.
- Cost and accessibility: About $8,000 per treatment at the main commercial provider before closing (Attia, 2022); the FDA cites up to thousands of dollars per infusion (FDA, 2019).
- Payer incentives: Young plasma for aging is not an approved indication (FDA update, 2024), so no institutional payer has an identifiable financial incentive favoring it; none was identified for plasma exchange either, and no payer-driven bias in guidelines or research funding was identified.
Interaction with Foundational Habits
- Sleep: Direction: none established. No trial measured sleep; the Oslo pilot recorded vivid dreams as a grade 2 event with probable treatment association, mechanism unknown (Søraas et al., 2026).
- Nutrition: Direction: indirect. Oslo patients were advised to eat extra protein (eggs or meat) during intensive exchange periods to offset protein loss (Søraas et al., 2026); plasma removal lowered serum albumin and total protein (Borsky et al., 2025).
- Exercise: Direction: none established for recipients. A Norwegian trial tests plasma from exercise-trained donors in early Alzheimer’s disease (NCT05068830), probing whether donor exercise matters.
- Stress management: Direction: none established. No study measured cortisol or stress response, and the mechanisms linking plasma factors to stress physiology are unexplored.
Monitoring Protocol & Defining Success
Baseline testing before any session, as in the Oslo pilot, covered recent biochemistry, absence of infection, a hepatitis B vaccination offer and antibody screening of donor plasma (Søraas et al., 2026). Baseline blood counts, calcium, clotting tests, albumin and immunoglobulin levels set safety margins and a reference for later change. Ongoing monitoring covers vital signs at every session and biochemistry about every 3 to 6 sessions in the Oslo pilot, then at 4 weeks and every 3 to 6 months after a course (common practice). Success is undefined: trials used safety and feasibility as primary endpoints (main outcomes), with function scores and biological-age readings as exploratory markers, and no validated success threshold exists.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Total calcium | 8.6–10.3 mg/dL (standard reference range) | Safety check: exchange can lower calcium | The Oslo pilot gave calcium before sessions and recorded five mild cases, two of them symptomatic (Søraas et al., 2026); hypocalcemic toxicity is a recognized exchange effect (Weinstein, 2001) |
| Hemoglobin and platelet count | Hemoglobin 13.5–17.5 g/dL men, 12.0–15.5 g/dL women; platelets 150–450 ×10⁹/L (standard reference range) | Safety check: baseline anemia delayed Oslo treatments | Part of a complete blood count; no fasting needed |
| Fibrinogen and INR | Fibrinogen 200–400 mg/dL; INR 0.8–1.1 (standard reference range) | Safety check: exchange removes clotting factors; warfarin users need INR tracking | INR (international normalized ratio) is a standardized clotting-time ratio; fibrinogen is a clotting protein |
| Albumin and total protein | Albumin 3.5–5.0 g/dL; total protein 6.0–8.3 g/dL (standard reference range) | Marker expected to change: plasma removal lowered both | Plasmapheresis without replacement lowered albumin and total protein (Borsky et al., 2025) |
| Immunoglobulins (IgG, IgA, IgM) | IgG 700–1,600 mg/dL; IgA 70–400 mg/dL; IgM 40–230 mg/dL (standard reference range) | Safety check: low IgA flags allergic risk; levels may fall with exchange | IgG, IgA and IgM are antibody classes; draw before sessions |
| Epigenetic age (DNA methylation clocks) | No established target; track change from the individual’s own baseline | Marker expected to change in trials, though an unvalidated surrogate | GrimAge is one clock; readings varied by clock in the randomized trials (Fuentealba et al., 2025; Borsky et al., 2025) |
Qualitative markers include:
- Sleep quality
- Energy levels
- Cognitive clarity
- Caregiver-rated everyday function
Emerging Research
- Frailty plasma trial: NCT03458429, a phase 1/2 trial (early-stage, safety-focused) of fresh frozen plasma from healthy donors in 30 older adults with frailty (age-related loss of physical reserve); primary endpoint is treatment-related adverse events; enrolling by invitation, primary completion December 2029. Clean safety would justify powered efficacy trials; adverse events would weaken the case.
- Exercise-trained donor plasma: NCT05068830, phase 2, 60 patients with early Alzheimer’s disease; primary endpoints are adverse events and protocol compliance; active, primary completion March 2027. A positive result would support donor-lifestyle effects; a null result would weaken them.
- Oslo plasma exchange: NCT06234436 lists 10 participants with unknown status and completion dates that have passed; the pilot was published with 12 patients and feasible procedures (Søraas et al., 2026).
- Alkahest surgery trial: NCT03981419 completed March 2021; results showed immune-signaling shifts in 38 patients (Gaudilliere et al., 2025). The Alzheimer’s plasma-fraction trial NCT03520998 completed May 2019; 47 patients showed no safety difference between dose levels and no cognitive decline, without a placebo group (Hannestad et al., 2020).
- Registered trials without results: NCT02803554 (young donor plasma, age biomarkers; 200 participants, completed January 2018) and NCT03353597 (young plasma, epigenetic senescence markers; status unknown, completion December 2022) report no results; NCT04241159 (young plasma, frailty and heart failure) was withdrawn.
- Open-label trial in a rare brain disease: Monthly young plasma in 5 patients with progressive supranuclear palsy (a rare brain disease affecting movement and balance) showed no detectable effect on progression versus historical controls (earlier patients used as the comparison) (VandeVrede et al., 2020).
- Placebo-controlled and Parkinson’s studies: A placebo-controlled plasma-fraction trial in severe Alzheimer’s disease reported similar adverse event rates, 44% versus 38% (Hannestad et al., 2021); 15 patients with Parkinson’s disease tolerated twice-weekly young plasma, with exploratory gains and no control group (Parker et al., 2020).
- Plasma removal evidence that could weaken the case: A randomized trial of plasma exchange found favorable shifts in 15 epigenetic clocks (Fuentealba et al., 2025), while plasmapheresis alone raised several clocks (Borsky et al., 2025); removal versus addition remains unresolved.
- Future research areas: Identifying active factors such as GDF11 (Egerman et al., 2015) and TIMP2 (Castellano et al., 2017); long-term exposure effects in mice (Zhang et al., 2023); and the Mayo Clinic donor-matching trial (NCT03887741), completed February 2024 without posted results.
Conclusion
Young plasma transfusion is the infusion of plasma from donors in their late teens to twenties into older recipients, in the hope that youthful blood signals can shift aspects of aging. The idea rests mainly on animal experiments, where results have been inconsistent across tissues and proposed active factors. In people, the studies are few, small and short. They show that infusions and large plasma exchanges can be carried out in a research setting, and some exploratory measures of daily function, immune-system activity and biological age moved favorably, but none has been confirmed in a controlled trial of healthy older adults, and no benefit reaches the higher evidence levels used here.
The risks are better documented than the benefits. Allergic reactions have appeared in the trials of more than one research group. Fluid overload, lung injury, fever, low blood pressure, calcium disturbances during large-volume exchange and a small residual infection risk are recognized with plasma products generally. Regulators have stated that the product is not approved for aging.
Much of the human evidence was produced or co-authored by companies and clinics that develop, sell or administer plasma products (for example Alkahest, Ambrosia and the plasma-exchange provider Circulate), and the blood-banking association whose plasma guidance regulators cite has members that handle plasma commercially; these financial interests are relevant to interpreting favorable reports. For health-conscious adults, the overall picture is of an unproven intervention with documented short-term harms and an evidence base too thin to define who, if anyone, benefits.